Literature DB >> 30926077

10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' reply.

Nicholas J Short1, Farhad Ravandi2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30926077     DOI: 10.1016/S2352-3026(19)30052-3

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN: 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  2 in total

1.  10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

Authors:  Courtney D DiNardo; Abhishek Maiti; Caitlin R Rausch; Naveen Pemmaraju; Kiran Naqvi; Naval G Daver; Tapan M Kadia; Gautam Borthakur; Maro Ohanian; Yesid Alvarado; Ghayas C Issa; Guillermo Montalban-Bravo; Nicholas J Short; Musa Yilmaz; Prithviraj Bose; Elias J Jabbour; Koichi Takahashi; Jan A Burger; Guillermo Garcia-Manero; Nitin Jain; Steven M Kornblau; Philip A Thompson; Zeev Estrov; Lucia Masarova; Koji Sasaki; Srdan Verstovsek; Alessandra Ferrajoli; William G Weirda; Sa A Wang; Sergej Konoplev; Zhining Chen; Sherry A Pierce; Jing Ning; Wei Qiao; Farhad Ravandi; Michael Andreeff; John S Welch; Hagop M Kantarjian; Marina Y Konopleva
Journal:  Lancet Haematol       Date:  2020-09-05       Impact factor: 18.959

2.  Efficacy of 10-day decitabine in acute myeloid leukemia.

Authors:  Ian M Bouligny; Vivek Mehta; Scott Isom; Leslie R Ellis; Rupali R Bhave; Dianna S Howard; Susan Lyerly; Megan Manuel; Sarah Dralle; Bayard L Powell; Timothy S Pardee
Journal:  Leuk Res       Date:  2021-02-12       Impact factor: 3.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.